Search results
Results from the WOW.Com Content Network
The following are settlements reached with US authorities against pharmaceutical companies to resolve allegations of "off-label" promotion of drugs. Under the Federal Food, Drug, and Cosmetic Act, it is illegal for pharmaceutical companies to promote their products for uses not approved by the Food and Drug Administration (FDA), and corporations that market drugs for off-label indications may ...
The settlement amount includes both the civil (False Claims Act) settlement and criminal fine. Glaxo's $3 billion settlement included the largest civil False Claims Act settlement on record, [1] and Pfizer’s $2.3 billion ($3.5 billion in 2022) settlement including a record-breaking $1.3 billion criminal fine. [2]
In 2020, Bayer settled most of the then-pending Roundup cases for up to $9.6 billion but failed to get a settlement covering future cases. More than 50,000 claims remain pending.
Bayer's patent covering its best-selling blood thinner Xarelto is invalid, London's High Court ruled on Friday in a blow to the German drugmaker. The company's blockbuster Xarelto drug generated ...
Side effects may include bleeding, most commonly from the nose, gastrointestinal tract (GI) or genitourinary system. [2] Compared to the risk of bleeding with warfarin use, direct factor Xa inhibitors have a higher risk of GI bleeding, but lower risk of bleeding in the brain. [2]
Bayer boss Werner Baumann's contract has been extended until 2024, in a show of support from the drugmaker's new chairman just months after the company agreed an $11 billion outline settlement of ...
Bayer and BASF were also ordered to pay Bader $15 million in damages. [135] On February 15, 2020, Monsanto and BASF were ordered to pay an additional $250 million in punitive damages. [136] [137] In June 2020, Bayer agreed to a settlement of up to $400 million for all 2015-2020 crop year dicamba claims, not including the $250 million judgement. [1]
Much of his case was initially dismissed by a trial judge, who agreed with Bayer that his failure-to-warn claims were barred by federal law. The 11th Circuit panel in July 2022 disagreed and ...